BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results
Go back to BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results| (NASDAQ: BTAI) | Delayed: 0.07 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.07 | 52 Week High | $ | |||
| Open | $0.07 | 52 Week Low | $ | |||
| Day High | $0.07 | P/E | N/A | |||
| Day Low | $0.07 | EPS | $ | |||
| Volume | 9,277,797 | |||||
